410
Chapter 11
399. Silverstein MJ. Incidence and treatment of ductal carcinoma
in situ
of
the breast.
Eur J Cancer
1997;33:10–11.
400. de Mascarel I, Bonichon F, MacGrogan G, et al. Application of
the Van Nuys prognostic index in a retrospective series of 367
ductal carcinomas
in situ
of the breast examined by serial macro-
scopic sectioning: practical considerations.
Breast Cancer Res Treat
2000;61:151–159.
401. Boland GP, Chan KC, Knox WF, et al. Value of the Van Nuys Prog-
nostic Index in prediction of recurrence of ductal carcinoma
in situ
after breast-conserving surgery.
Br J Surg
2003;90:426–432.
402. Warnberg F, Nordgren H, Bergh J, et al. Ductal carcinoma
in situ
of
the breast from a population-defined cohort: an evaluation of new his-
topathological classification systems.
Eur J Cancer
1999;35:714–720.
403. Silverstein MJ. Ductal carcinoma
in situ
of the breast: the Van Nuys
experience by treatment.
Breast J
1997;3:232–237.
404. Solin LJ, McCormick B, Recht A, et al. Mammographically detected,
clinically occult ductal carcinoma
in situ
treated with breast-con-
serving surgery and definitive breast irradiation.
Cancer J Sci Am
1996;2:158–165.
405. Fowble B. The results of conservative surgery and radiation for
mammographically detected ductal carcinoma
in situ
.
Breast J
1997;3:238–241.
406. Silverstein MJ, Lagios MD, Martino S, et al. Outcome after invasive
local recurrence in patients with ductal carcinoma
in situ
of the breast.
J Clin Oncol
1998;16:1367–1373.
407. Silverstein MJ, Lagios MD. Choosing treatment for patients with
ductal carcinoma
in situ
: fine tuning the University of Southern
California/Van NuysPrognostic Index.
J Natl Cancer Inst Monogr
2010;2010(41):193–196.
408. Altintas S, Toussaint J, Durbecq V, et al. Fine tuning of the Van Nuys
prognostic index (VNPI) 2003 by integrating the genomic grade in-
dex (GGI): new tools for ductal carcinoma
in situ
(DCIS).
Breast J
2011;17:343–351.
409. Kelley L, Silverstein M, Guerra L. Analyzing the risk of recurrence af-
ter mastectomy for DCIS: a new use for the USC/Van Nuys Prognostic
Index.
Ann Surg Oncol
2011;18:459–462.
410. Rudloff U, Jacks LM, Goldberg JI, et al. Nomogram for predicting the
risk of local recurrence after breast-conserving surgery for ductal car-
cinoma
in situ
.
J Clin Oncol
2010;28:3762–3769.
411. Yim, Meric-Bernstein F, Kuerer HM, et al. Evaluation of a breast can-
cer nomogram for predicting risk of ipsilateral breast tumor recur-
rence in patients with ductal carcinoma
in situ
after local excision.
J Clin Oncol
2012;30:600–607.
412. Thomas M, Goldstein NS, Vicini FA, et al. The association of age at
diagnosis with pathologic features in patients with duct carcinoma
in
situ
of the breast.
Mod Pathol
2000;13:47A.
413. Adepoju LJ, Symmans WF, Babiera GV, et al. Impact of concurrent
proliferative high-risk lesions on the risk of ipsilateral breast carci-
noma recurrence and contralateral breast carcinoma development in
patients with ductal carcinoma
in situ
treated with breast-conserving
therapy.
Cancer
2006;106:42–50.
414. Cuzick J, Sestak I, Pinder SE, et al. Effect of tamoxifen and radiother-
apy in women with locally excised ductal carcinoma
in situ
: long-term
results from the UK/ANZ DCIS trial.
Lancet Oncol
2011;12:21–29.
415. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of in-
traductal breast cancer: National Surgical Adjuvant Breast and Bowel
Project B-24 randomised controlled trial.
Lancet
1999;353:1993–2000.
416. Allred DC, Anderson SJ, Paik S, et al. Adjuvant tamoxifen reduces
subsequent breast cancer in women with estrogen receptor-positive
ductal carcinoma
in situ
: a study based on NSABP protocol B-24.
J
Clin Oncol
2012;30:1268–1273.
417. Vogel VG, Costantino JP, Wickerham DL, et al. Update of the Na-
tional Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen
and Raloxifene (STAR) P-2 Trial: preventing breast cancer.
Cancer
Prev Res (Phila)
2010;3:696–706.
418. Morrow M, O’Sullivan MJ. The dilemma of DCIS.
Breast
2007;16(Suppl. 2):S59–S62.
419. Allegra CJ, Aberle DR, Ganschow P, et al. National Institutes of Health
State-of-the-Science Conference statement: diagnosis and manage-
ment of ductal carcinoma
in situ,
September 22–24, 2009.
J Natl Can-
cer Inst
2010;102:161–169.
420. Cutuli B, Lemanski C, Fourquet A, et al. Breast-conserving surgery
with or without radiotherapy vs mastectomy for ductal carcinoma
in
situ
: French Survey experience.
Br J Cancer
2009;100:1048–1054.
377. MacDonald HR, Silverstein MJ, Mabry H, et al. Local control in duc-
tal carcinoma
in situ
treated by excision alone: incremental benefit of
larger margins.
Am J Surg
2005;190:521–525.
378. Wong JS, Kaelin CM, Troyan SL, et al. Prospective study of wide ex-
cision alone for ductal carcinoma
in situ
of the breast.
J Clin Oncol
2006;24:1031–1036.
379. Montague ED. Conservative surgery and radiation therapy in the
treatment of operable breast cancer.
Cancer
1984;53:700–704.
380. Solin LJ, Gray R, Baehner FL. A quantitative multigene RT-PCR assay
for predicting recurrence risk after surgical excision alone without ir-
radiation for ductal carcinoma
in situ
(DCIS): a prospective validation
study of the DCIS score from ECOG E5194. Presented at: the 2011
CTRC-AACR San Antonio Breast Cancer Symposium; December
6–10, 2011 (Abstract S4–S6).
381. Prat A, Perou CM. Deconstructing the molecular portraits of breast
cancer.
Mol Oncol
2011;5:5–23.
382. Recht A, Danoff BS, Solin LJ, et al. Intraductal carcinoma of the breast:
results of treatment with excisional biopsy and irradiation.
J Clin On-
col
1985;3:1339–1343.
383. Zafrani B, Fourquet A, Vilcoq JR, et al. Conservative management of
intraductal breast carcinoma with tumorectomy and radiation ther-
apy.
Cancer
1986;57:1299–1301.
384. Bornstein BA, Recht A, Connolly JL, et al. Results of treating ductal
carcinoma
in situ
of the breast with conservative surgery and radiation
therapy.
Cancer
1991;67:7–13.
385. Solin LJ, Recht A, Fourquet A, et al. Ten-year results of breast-
conserving surgery and definitive irradiation for intraductal carcinoma
(ductal carcinoma
in situ
) of the breast.
Cancer
1991;68:2337–2344.
386. Solin LJ, Fourquet A, Vicini FA, et al. Long-term outcome after breast-
conservation treatment with radiation for mammographically detected
ductal carcinoma
in situ
of the breast.
Cancer
2005;103:1137–1146.
387. Fisher B, Land S, Mamounas E, et al. Prevention of invasive breast
cancer in women with ductal carcinoma
in situ
: an update of the na-
tional surgical adjuvant breast and bowel project experience.
Semin
Oncol
2001;28:400–418.
388. Julien JP, Bijker N, Fentiman IS, et al. Radiotherapy in breast-
conserving treatment for ductal carcinoma
in situ
: first results of
the EORTC randomised phase III trial 10853. EORTC Breast Can-
cer Cooperative Group and EORTC Radiotherapy Group.
Lancet
2000;355:528–533.
389. Bijker N, Meijnen P, Peterse JL, et al. Breast-conserving treatment
with or without radiotherapy in ductal carcinoma-in-situ: ten-year
results of European Organisation for Research and Treatment of Can-
cer randomized phase III trial 10853—a study by the EORTC Breast
Cancer Cooperative Group and EORTC Radiotherapy Group.
J Clin
Oncol
2006;24:3381–3387.
390. Kane RL, Virnig BA, Shamliyan T, et al. The impact of surgery, ra-
diation, and systemic treatment on outcomes in patients with ductal
carcinoma
in situ
.
J Natl Cancer Inst Monogr
2010;2010(41):130–133.
391. Punglia RS, Burstein HJ, Weeks JC. Radiation therapy for ductal carci-
noma
in situ
: a decision analysis.
Cancer
2012;118:603–611.
392. Zauls AJ, Watkins JM, Wahlquist AE, et al. Outcomes in women
treated with MammoSite brachytherapy or whole breast irradiation
stratified by ASTRO Accelerated Partial Breast Irradiation Consensus
Statement Groups.
Int J Radiat Oncol Biol Phys
2012;82:21–29.
393. Park SS, Grills IS, Chen PY, et al. Accelerated partial breast irradia-
tion for pure ductal carcinoma
in situ
.
Int J Radiat Oncol Biol Phys
2011;81:403–408.
394. Wong P, Lambert C, Agnihotram RV, et al. Ductal carcinoma
in situ
—
the influence of the radiotherapy boost on local control.
Int J Radiat
Oncol Biol Phys
2012;82:e153–e158.
395. Arvold ND, Punglia RS, Hughes ME, et al. Pathologic characteristics
of second breast cancers after breast conservation for ductal carci-
noma
in situ
.
Cancer
2012;118:6022–6030.
396. Solin LJ, Yeh I-T, Kurtz J, et al. Ductal carcinoma
in situ
(intraductal
carcinoma) of the breast treated with breast-conserving surgery and
definitive irradiation. Correlation of pathologic parameters with out-
come of treatment.
Cancer
1993;71:2532–2542.
397. Kuske RR, Bean JM, Garcia DM, et al. Breast conservation therapy
for intraductal carcinoma of the breast.
Int J Radiat Oncol Biol Phys
1993;26:391–396.
398. Fisher ER, Dignam J, Tan-Chiu E, et al. Pathologic findings from the
National Surgical Adjuvant Breast Project (NSABP) eight-year update
of Protocol B-17: intraductal carcinoma.
Cancer
1999;86:429–438.
